Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FDG-PET/CT based response-adapted treatment.
de Geus-Oei LF, Vriens D, Arens AI, Hutchings M, Oyen WJ. de Geus-Oei LF, et al. Cancer Imaging. 2012 Sep 28;12(2):324-35. doi: 10.1102/1470-7330.2012.9006. Cancer Imaging. 2012. PMID: 23023063 Free PMC article. Review.
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.
Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, Brice P, Hutchings M, Gastinne T, Liu R, Burggraaff CN, Nijland M, Tonino SH, Arens AIJ, Valkema R, van Tinteren H, Lopez-Yurda M, Diepstra A, De Jong D, Hagenbeek A. Kersten MJ, et al. Among authors: arens aij. Haematologica. 2021 Apr 1;106(4):1129-1137. doi: 10.3324/haematol.2019.243238. Haematologica. 2021. PMID: 32273476 Free PMC article. Clinical Trial.
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP.
Driessen J, Kersten MJ, Visser L, van den Berg A, Tonino SH, Zijlstra JM, Lugtenburg PJ, Morschhauser F, Hutchings M, Amorim S, Gastinne T, Nijland M, Zwezerijnen GJC, Boellaard R, de Vet HCW, Arens AIJ, Valkema R, Liu RDK, Drees EEE, de Jong D, Plattel WJ, Diepstra A; HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC). Driessen J, et al. Among authors: arens aij. Leukemia. 2022 Dec;36(12):2853-2862. doi: 10.1038/s41375-022-01717-8. Epub 2022 Oct 14. Leukemia. 2022. PMID: 36241696
Interobserver Agreement of Interim and End-of-Treatment 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials.
Burggraaff CN, Cornelisse AC, Hoekstra OS, Lugtenburg PJ, De Keizer B, Arens AIJ, Celik F, Huijbregts JE, De Vet HCW, Zijlstra JM; HOVON Imaging Working Group. Burggraaff CN, et al. Among authors: arens aij. J Nucl Med. 2018 Dec;59(12):1831-1836. doi: 10.2967/jnumed.118.210807. Epub 2018 May 4. J Nucl Med. 2018. PMID: 29728515 Free article. Clinical Trial.
PET imaging during hypoglycaemia to study adipose tissue metabolism.
Boss M, Rooijackers HMM, Buitinga M, Janssen MJR, Arens AIJ, de Geus-Oei LF, Salm LP, de Galan BE, Gotthardt M. Boss M, et al. Among authors: arens aij. Eur J Clin Invest. 2019 Jul;49(7):e13120. doi: 10.1111/eci.13120. Epub 2019 Apr 29. Eur J Clin Invest. 2019. PMID: 31002171 Free PMC article.
18F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study.
Burggraaff CN, Eertink JJ, Lugtenburg PJ, Hoekstra OS, Arens AIJ, de Keizer B, Heymans MW, van der Holt B, Wiegers SE, Pieplenbosch S, Boellaard R, de Vet HCW, Zijlstra JM; HOVON Imaging Working Group and the HOVON Lymphoma Working Group. Burggraaff CN, et al. Among authors: arens aij. J Nucl Med. 2022 Jul;63(7):1001-1007. doi: 10.2967/jnumed.121.262205. Epub 2021 Oct 21. J Nucl Med. 2022. PMID: 34675112 Free PMC article. Clinical Trial.
Anakinra injection site reaction on FDG PET/CT.
Arens AI, Vriens D, Janssen M, Simon A, Oyen WJ. Arens AI, et al. Clin Nucl Med. 2015 Jun;40(6):492-3. doi: 10.1097/RLU.0000000000000747. Clin Nucl Med. 2015. PMID: 25742228
52 results